Xanomeline Enteric Capsule + Xanomeline/Trospium Chloride Capsule for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Jun 2025: Trial registered, NCT07011732
  2. 10 Jul 2025: Trial started, NCT07011732

The trials

NCT07011732: A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

State
Under way
Phase
Phase 3
People
426 planned
Started
10 Jul 2025
Primary completion
24 Nov 2028
Arms
KarXT + KarX-EC
Results
None posted
  1. 10 Jun 2025: Trial registered
  2. 10 Jul 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.